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background:  Fractional flow reserve (FFR) and the index of microcirculatory resistance (IMR) predict outcomes in non-transplant patients; 
their value in heart transplant recipients has not been well-studied. The aim of this study is to determine the prognostic value of assessing 
coronary physiology early after heart transplantation.
methods:  Seventy-four transplant recipients had coronary physiology assessed at both baseline and 1 year. The primary endpoint was the 
composite of death and retransplantation at a mean follow-up of 4.5±3.5 years.
results:  A high IMR (≥20) measured at one year was a significant predictor of death/retransplantation (40.9% vs. 13.5%, p=0.025), 
although FFR was not. However, the rate of death/retransplantation was lowest in patients with high FFR (≥0.90) and low IMR (<20) 
measured at 1 year compared to those with low FFR (<0.90) and high IMR (≥20) (7.7% vs 60%, p= 0.004) (Figure1). Patients with a 
decrease in IMR from baseline to 1 year had lower death/retransplantation rates compared to those patients with an increase in IMR 
(18.0% vs. 29.2%, p=0.027).
Conclusion:  Measures of coronary physiology and in particular microvascular dysfunction determined early after heart transplantation are 
significant predictors of late adverse events.
